MINNEAPOLIS, May 31, 2011 /PRNewswire/ — Uroplasty, Inc.
(NASDAQ:
UPI), announced today that the United Kingdom’s National
Institute for Health and Clinical Excellence (NICE) issued guidance
on percutaneous tibial nerve stimulation (PTNS) for the treatment
of faecal incontinence. In October 2010, NICE issued similar
guidance on PTNS treatment for overactive bladder.
“This NICE guidance should encourage physicians in the UK and
Europe to use our Urgent® PC Neuromodulation System for PTNS
treatments for this often difficult-to-treat affliction. This
guidance affirms the evidence that PTNS is efficacious in reducing
the symptoms of faecal incontinence without major safety concerns,”
said David Kaysen, President and CEO of Uroplasty.
In the UK, NICE makes recommendations to the National Health
Service on new and existing medicines, treatments and procedures
with the goal of improving health and treating and preventing poor
health. A copy of the NICE guidance may be found at www.nice.org.uk.
About Uroplasty, Inc. Uroplasty, Inc., headquartered in
Minnetonka, Minnesota, with wholly-owned subsidiaries in The
Netherlands and the United Kingdom, is a medical device company
that develops, manufactures and markets innovative proprietary
products for the treatment of voiding dysfunctions. Our focus
is the continued commercialization of our Urgent PC Neuromodulation
System, which we believe is the only FDA-cleared minimally
invasive, office-based neuromodulation therapy for the treatment of
overactive bladder and the associated symptoms of urinary urgency,
urinary frequency and urge incontinence.
We also offer Macroplastique Implants®, an injectable
urethral bulking agent for the treatment of adult female stress
urinary incontinence primarily due to intrinsic sphincter
deficiency. For more inf
‘/>”/>
SOURCE
